# Phase III Clinical Trial of Quadrivalent Influenza Virus Split Vaccine

> **NCT06800950** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Institute of Medical Biology, Chinese Academy of Medical Sciences** · enrollment: 4400 (estimated)

## Conditions studied

- Influenza, Human
- Influenza, Human Prevention
- Influenza a
- Influenza B
- Influenza Viral Infections

## Interventions

- **BIOLOGICAL:** QIV
- **BIOLOGICAL:** QIV Control

## Key facts

- **NCT ID:** NCT06800950
- **Lead sponsor:** Institute of Medical Biology, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02-08
- **Primary completion:** 2025-07-15
- **Final completion:** 2025-10-15
- **Target enrollment:** 4400 (ESTIMATED)
- **Last updated:** 2025-01-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06800950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06800950, "Phase III Clinical Trial of Quadrivalent Influenza Virus Split Vaccine". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06800950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*